[go: up one dir, main page]

ATE350040T1 - Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin - Google Patents

Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin

Info

Publication number
ATE350040T1
ATE350040T1 AT00910474T AT00910474T ATE350040T1 AT E350040 T1 ATE350040 T1 AT E350040T1 AT 00910474 T AT00910474 T AT 00910474T AT 00910474 T AT00910474 T AT 00910474T AT E350040 T1 ATE350040 T1 AT E350040T1
Authority
AT
Austria
Prior art keywords
prostaglandin
pharmaceutical composition
nsaid
composition containing
composition
Prior art date
Application number
AT00910474T
Other languages
English (en)
Inventor
Aomar Ouali
Abul Kalam Azad
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Application granted granted Critical
Publication of ATE350040T1 publication Critical patent/ATE350040T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00910474T 1999-03-22 2000-03-20 Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin ATE350040T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/273,692 US6183779B1 (en) 1999-03-22 1999-03-22 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin

Publications (1)

Publication Number Publication Date
ATE350040T1 true ATE350040T1 (de) 2007-01-15

Family

ID=23045012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910474T ATE350040T1 (de) 1999-03-22 2000-03-20 Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin

Country Status (7)

Country Link
US (2) US6183779B1 (de)
EP (1) EP1162975B1 (de)
AT (1) ATE350040T1 (de)
AU (1) AU3269200A (de)
CA (1) CA2301378C (de)
DE (1) DE60032749T2 (de)
WO (1) WO2000056339A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
KR20020063871A (ko) * 1999-10-01 2002-08-05 노턴 헬스케어 리미티드 항 - 염증성 약학적 제제형
KR20030019326A (ko) * 2000-03-21 2003-03-06 니뽄 신야쿠 가부시키가이샤 방출 제어형 경구 투여 제제
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
RU2196570C1 (ru) * 2001-12-13 2003-01-20 ЗАО "Медисорб" Фармацевтическая композиция, обладающая противовоспалительной активностью
GB2386817B (en) * 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
NZ535456A (en) * 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
WO2004091579A1 (en) * 2003-04-16 2004-10-28 Pharmacia Corporation Stabilized prostaglandin formulation
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1568369A1 (de) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US20070224259A1 (en) * 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
CA2623201A1 (en) * 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
CA2633266C (en) * 2005-12-16 2011-08-02 Hanmi Pharm. Co., Ltd. Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
US20070190139A1 (en) * 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
SI2124556T1 (sl) * 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP2167048B1 (de) 2007-05-30 2016-10-26 Wockhardt Limited Neue tabletten-dosierform
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
ES2620672T3 (es) * 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
WO2010020772A2 (en) * 2008-08-22 2010-02-25 Reckitt Benckiser Healthcare (Uk) Limited Improvements in or relating to compositions
WO2010029335A1 (en) 2008-09-09 2010-03-18 Astrazeneca Uk Limited Method for delivering a pharmaceutical composition to patient in need thereof
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
EP2445499A4 (de) 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
EP2451274B1 (de) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
CN102647971B (zh) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 用于包含美洛昔康的组合物的容器
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN102336693B (zh) * 2010-07-21 2014-01-22 上海天伟生物制药有限公司 卡前列素氨丁三醇的晶体及其制备方法和用途
US20140271783A1 (en) * 2011-10-14 2014-09-18 Purdue Research Foundation Prefabricated pharmaceutical dosage forms from functional polymer films
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN105435239B (zh) * 2014-08-29 2019-04-26 武汉光谷人福生物医药有限公司 美索舒利薄膜衣片及其制备方法
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781429A (en) 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3954787A (en) 1974-06-18 1976-05-04 Pfizer Inc. Stabilized E-series prostaglandins
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
DK0527887T3 (da) * 1990-05-03 1995-07-03 Searle & Co Farmaceutisk præparat
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
CA2301883A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
CA2241342C (en) 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
GB9819685D0 (en) 1998-09-10 1998-11-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations

Also Published As

Publication number Publication date
DE60032749D1 (de) 2007-02-15
EP1162975A1 (de) 2001-12-19
WO2000056339A1 (en) 2000-09-28
US6287600B1 (en) 2001-09-11
US6183779B1 (en) 2001-02-06
CA2301378A1 (en) 2000-09-22
CA2301378C (en) 2005-07-26
DE60032749T2 (de) 2007-10-18
EP1162975B1 (de) 2007-01-03
AU3269200A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
NO20001290D0 (no) Multiple-enhet sammensetninger av ikke-steroid anti- inflammatorisk medikament substans (NSAID) med modifisert frigjøring
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
JP2005515966A5 (de)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
JP2006516570A5 (de)
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
JP2008543936A5 (de)
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AP2003002763A0 (en) Controlled release formulations for oral administration
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
NO20080244L (no) Doseringsstyring for prasugrel
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
JP2005525329A5 (de)
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény
JP2003523385A5 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties